ISRG vs MBOT

Intuitive Surgical (ISRG) continues to demonstrate strong operational performance, evidenced by its Q4 2025 revenue growth of 18.8% YoY and robust EPS beat. It maintains its undisputed leadership in robotic-assisted surgery, supported by a growing installed base of 11,423 da Vinci systems and impressive Ion system adoption. The company's formidable moat, built on IP, high switching costs, and exte...

Microbot Medical remains an intriguing high-risk, high-reward play in the rapidly expanding robotic endovascular surgery market, buoyed by its FDA-cleared LIBERTY system and proprietary technology. While the previous $15 million public offering temporarily mitigated immediate financial fragility, providing 7-8 months of runway as of late January 2026, approximately 53 days have passed. Assuming a ...